GSK’s Altabax “Not Approvable” For Traumatic Lesions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has revised its “approvable” decision from December and is now saying the secondarily infected traumatic lesions indication is “not approvable.”